Market capitalization | $308.09m |
Enterprise Value | $8.08m |
P/E (TTM) P/E ratio | 7.83 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.05 |
P/S ratio (TTM) P/S ratio | 1.88 |
P/B ratio (TTM) P/B ratio | 0.93 |
Revenue growth (TTM) Revenue growth | 3.40% |
Revenue (TTM) Revenue | $163.78m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
10 Analysts have issued a Voyager Therapeutics, Inc. forecast:
10 Analysts have issued a Voyager Therapeutics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 164 164 |
3%
3%
|
|
Gross Profit | 159 159 |
3%
3%
|
|
EBITDA | 14 14 |
70%
70%
|
EBIT (Operating Income) EBIT | 9.08 9.08 |
79%
79%
|
Net Profit | 26 26 |
51%
51%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Alfred Sandrock |
Employees | 162 |
Founded | 2013 |
Website | www.voyagertherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.